vimarsana.com
Home
Live Updates
Nintedanib Under Review for Children With Fibrosing Interstitial Lung Disease : comparemela.com
Nintedanib Under Review for Children With Fibrosing Interstitial Lung Disease
The FDA has accepted the sNDA for nintedanib for children and adolescents 6 to 17 years of age with fibrosing interstitial lung disease.
Related Keywords
Colorado ,
United States ,
Robin Deterding ,
Drug Administration ,
New Drug Application ,
Breathing Institute ,
Hospital Colorado ,
comparemela.com © 2020. All Rights Reserved.